慢性髓系肿瘤患者对新冠病毒疫苗接种的抗体反应受损。 - Suppr

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.

作者信息

Chowdhury Onima, Bruguier Hannah, Mallett Garry, Sousos Nikolaos, Crozier Kirsty, Allman Caroline, Eyre David, Lumley Sheila, Strickland Marie, Karali Christina S, Murphy Lauren, Sternberg Alex, Jeffery Katie, Mead Adam J, Peniket Andy, Psaila Bethan

机构信息

MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

National Institute of Health Research Oxford Biomedical Research Centre, Oxford, UK.

出版信息

Br J Haematol. 2021 Sep;194(6):1010-1015. doi: 10.1111/bjh.17644. Epub 2021 Jun 24.

DOI:10.1111/bjh.17644

PMID:34132395

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8444839/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a953/8444839/1851f1d40c18/BJH-194-1010-g001.jpg

相似文献

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.

Br J Haematol. 2021 Sep;194(6):1010-1015. doi: 10.1111/bjh.17644. Epub 2021 Jun 24.

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.

Br J Haematol. 2021 Sep;194(6):999-1006. doi: 10.1111/bjh.17568. Epub 2021 Jun 3.

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.

Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.

Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?

Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.

Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.

Microbiol Spectr. 2021 Dec 22;9(3):e0120221. doi: 10.1128/Spectrum.01202-21. Epub 2021 Nov 24.

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.

Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23.

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.

JAMA. 2021 Oct 19;326(15):1533-1535. doi: 10.1001/jama.2021.15125.

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.

Ann Hematol. 2022 Aug;101(8):1825-1834. doi: 10.1007/s00277-022-04866-z. Epub 2022 May 21.

Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19).

Blood. 2021 Sep 16;138(11):996-999. doi: 10.1182/blood.2021012790.

引用本文的文献

Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis.

JMA J. 2024 Apr 15;7(2):153-171. doi: 10.31662/jmaj.2023-0171. Epub 2024 Apr 1.

Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.

Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.

Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies.

Vaccines (Basel). 2023 Mar 15;11(3):662. doi: 10.3390/vaccines11030662.

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.

Haematologica. 2023 Feb 1;108(2):653-654. doi: 10.3324/haematol.2022.281902.

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.

Trends Mol Med. 2022 Dec;28(12):1082-1099. doi: 10.1016/j.molmed.2022.07.006. Epub 2022 Aug 3.

A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.

Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12.

Seroprevalence study prior and post vaccination in cancer patients in principality of Andorra (COVONCO study).

J Cancer Res Clin Oncol. 2023 Jul;149(7):2883-2892. doi: 10.1007/s00432-022-04141-8. Epub 2022 Jul 9.

SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies.

Blood Rev. 2022 Nov;56:100984. doi: 10.1016/j.blre.2022.100984. Epub 2022 Jun 12.

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.

Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3.

COVID-19 vaccination in cancer patients: a narrative review.

J Int Med Res. 2022 Mar;50(3):3000605221086155. doi: 10.1177/03000605221086155.

本文引用的文献

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.

Clin Microbiol Infect. 2021 Oct;27(10):1516.e7-1516.e14. doi: 10.1016/j.cmi.2021.05.041. Epub 2021 Jun 7.

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.

Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.

Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm.

Leukemia. 2021 Aug;35(8):2424-2430. doi: 10.1038/s41375-021-01143-2. Epub 2021 Feb 12.

When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities.

Blood Rev. 2021 May;47:100775. doi: 10.1016/j.blre.2020.100775. Epub 2020 Nov 9.

Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms.

Br J Haematol. 2021 Apr;193(1):150-154. doi: 10.1111/bjh.17096. Epub 2020 Nov 7.

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.

Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.

Factors associated with COVID-19-related death using OpenSAFELY.

Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.

Lancet. 2020 Jun 20;395(10241):1919-1926. doi: 10.1016/S0140-6736(20)31173-9. Epub 2020 May 28.

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.

Haematologica. 2011 Feb;96(2):307-14. doi: 10.3324/haematol.2010.032664. Epub 2010 Oct 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.

作者信息

机构信息

MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

National Institute of Health Research Oxford Biomedical Research Centre, Oxford, UK.

出版信息

Br J Haematol. 2021 Sep;194(6):1010-1015. doi: 10.1111/bjh.17644. Epub 2021 Jun 24.

DOI:10.1111/bjh.17644

PMID:34132395

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8444839/

Abstract

摘要

相似文献

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.

Br J Haematol. 2021 Sep;194(6):1010-1015. doi: 10.1111/bjh.17644. Epub 2021 Jun 24.

Br J Haematol. 2021 Sep;194(6):999-1006. doi: 10.1111/bjh.17568. Epub 2021 Jun 3.

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.

Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.

Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?

Am J Hematol. 2021 Sep 1;96(9):E321-E324. doi: 10.1002/ajh.26248. Epub 2021 Jun 2.

Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.

Microbiol Spectr. 2021 Dec 22;9(3):e0120221. doi: 10.1128/Spectrum.01202-21. Epub 2021 Nov 24.

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.

Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23.

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.

JAMA. 2021 Oct 19;326(15):1533-1535. doi: 10.1001/jama.2021.15125.

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.

Ann Hematol. 2022 Aug;101(8):1825-1834. doi: 10.1007/s00277-022-04866-z. Epub 2022 May 21.

Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19).

Blood. 2021 Sep 16;138(11):996-999. doi: 10.1182/blood.2021012790.

引用本文的文献

Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis.

JMA J. 2024 Apr 15;7(2):153-171. doi: 10.31662/jmaj.2023-0171. Epub 2024 Apr 1.

Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.

Adverse Hematological Effects of COVID-19 Vaccination and Pathomechanisms of Low Acquired Immunity in Patients with Hematological Malignancies.

Vaccines (Basel). 2023 Mar 15;11(3):662. doi: 10.3390/vaccines11030662.

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.

Haematologica. 2023 Feb 1;108(2):653-654. doi: 10.3324/haematol.2022.281902.

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer.

Trends Mol Med. 2022 Dec;28(12):1082-1099. doi: 10.1016/j.molmed.2022.07.006. Epub 2022 Aug 3.

A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.

Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12.

Seroprevalence study prior and post vaccination in cancer patients in principality of Andorra (COVONCO study).

J Cancer Res Clin Oncol. 2023 Jul;149(7):2883-2892. doi: 10.1007/s00432-022-04141-8. Epub 2022 Jul 9.

SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies.

Blood Rev. 2022 Nov;56:100984. doi: 10.1016/j.blre.2022.100984. Epub 2022 Jun 12.

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.

Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3.

COVID-19 vaccination in cancer patients: a narrative review.

J Int Med Res. 2022 Mar;50(3):3000605221086155. doi: 10.1177/03000605221086155.

本文引用的文献

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.

Clin Microbiol Infect. 2021 Oct;27(10):1516.e7-1516.e14. doi: 10.1016/j.cmi.2021.05.041. Epub 2021 Jun 7.

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.

Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.

Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm.

Leukemia. 2021 Aug;35(8):2424-2430. doi: 10.1038/s41375-021-01143-2. Epub 2021 Feb 12.

When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities.

Blood Rev. 2021 May;47:100775. doi: 10.1016/j.blre.2020.100775. Epub 2020 Nov 9.

Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms.

Br J Haematol. 2021 Apr;193(1):150-154. doi: 10.1111/bjh.17096. Epub 2020 Nov 7.

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.

Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.

Factors associated with COVID-19-related death using OpenSAFELY.

Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.

Lancet. 2020 Jun 20;395(10241):1919-1926. doi: 10.1016/S0140-6736(20)31173-9. Epub 2020 May 28.

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.

Haematologica. 2011 Feb;96(2):307-14. doi: 10.3324/haematol.2010.032664. Epub 2010 Oct 22.

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献